CRMD - Latest News
CorMedix Inc. (CRMD), operates in Healthcare / Biotechnology, trades on NASDAQ.
Market capitalization stands near $588.3M. Trailing twelve-month P/E ratio is 3.63. Beta to the broader market is 1.46.
The article list below shows the most recent CRMD headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.
Recent CRMD Headlines
CRMD Q1 Earnings Beat on DefenCath Momentum, Guidance Raised
zacks.com - May 15, 2026
CorMedix beats Q1 estimates as DefenCath demand surges and raises 2026 guidance on stronger execution and growing profitability.
Cormedix Therapeutics to Participate in two Upcoming Investor Conferences
globenewswire.com - May 15, 2026
PARSIPPANY, N. J.
CorMedix Stock Jumps As DefenCath Fuels Q1 Beat, 2026 Outlook Raised
benzinga.com - May 14, 2026
CorMedix Therapeutics Inc. (NASDAQ:CRMD) raised its full-year 2026 revenue and adjusted EBITDA guidance after reporting strong first-quarter results
CorMedix Inc. (CRMD) Q1 2026 Earnings Call Transcript
seekingalpha.com - May 14, 2026
CorMedix Inc.
CorMedix Q1 Earnings Call Highlights
marketbeat.com - May 14, 2026
CorMedix NASDAQ: CRMD reported sharply higher first-quarter 2026 revenue and profit, driven by continued adoption of DefenCath and the addition of pro
How News Affects CRMD Options Pricing
Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track CRMD's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.
Frequently asked CRMD news questions
- What is the latest CRMD news headline?
- The most recent CRMD headline (May 15, 2026) is "CRMD Q1 Earnings Beat on DefenCath Momentum, Guidance Raised". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.
- How fresh is the CRMD news on this page?
- News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.
- What CRMD news moves options pricing?
- Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.
- How can I track unusual CRMD options activity related to news?
- Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.